Table 3.
Logistic regression analysis of the risk factors for LOS >30 days
| Parameters | Univariate analysis | Multivariate analysis (plus CCI model) | Multivariate analysis (plus CDC model) | |||
|---|---|---|---|---|---|---|
| OR (95% CI) | p value | OR (95% CI) | p value | OR (95% CI) | p value | |
| Female | 1.06 (0.69–1.62) | 0.42 | ||||
| Age at surgery (10-year intervals) | 1.32 (1.17–1.49) | <0.01* | 1.24 (1.07–1.45) | 0.01* | 1.38 (1.18–1.61) | 0.01* |
| Disease duration (1-month intervals) | 0.99 (0.99–1.00) | 0.15 | 0.99 (0.97–1.02) | 0.88 | 1.00 (0.99–1.00) | 0.68 |
| Severe disease | 2.21 (1.47–3.32) | <0.01* | 1.07 (0.49–2.33) | 0.84 | 1.19 (0.54–2.61) | 0.64 |
| Alb (per 1 g/dL) | 0.58 (0.47–0.72) | <0.01* | 0.71 (0.46–1.12) | 0.14 | 0.61 (0.39–0.96) | 0.03* |
| CRP (per 1 g/dL) | 1.06 (1.02–1.09) | <0.01* | 1.03 (0.97–1.09) | 0.29 | 1.01 (0.95–1.06) | 0.72 |
| Total lymphocyte count/μL | 0.99 (0.99–1.00) | 0.37 | ||||
| BMI≥25 | 1.25 (0.59–2.62) | 0.33 | ||||
| ASA score ≥3 | 1.71 (1.09–2.68) | 0.01* | 1.94 (1.00–3.76) | 0.04* | 1.61 (0.83–3.10) | 0.14 |
| Total given PSL dose (per 1 mg) | 1.00 (0.99–1.00) | 0.80 | ||||
| Immunomodulators | 0.81 (0.53–1.26) | 0.85 | ||||
| Calcineurin inhibitors | 1.45 (0.88–2.37) | 0.09 | 1.62 (0.88–2.95) | 0.11 | 1.73 (0.93–3.21) | 0.08 |
| Janus kinase inhibitors | 0 | 0.38 | ||||
| Biologics | 0.71 (0.45–1.12) | 0.94 | ||||
| Cancer/dysplasia | 0.61 (0.38–0.97) | 0.02* | 1.24 (0.602.551) | 0.55 | 1.55 (0.74–3.24) | 0.52 |
| Refractory | 1.04 (0.69–1.57) | 0.45 | ||||
| Massive bleeding | 1.76 (0.86–3.59) | 0.08 | 1.12 (0.40–3.09) | 0.82 | 1.34 (0.51–3.53) | 0.23 |
| Perforation | 1.71 (0.43–6.70) | 0.32 | ||||
| Urgent/emergent surgery | 2.21 (1.45–3.36) | <0.01* | 1.43 (0.61–3.31) | 0.40 | 1.34 (0.58–3.13) | 0.48 |
| Laparoscopic surgery | 1.20 (0.61–2.37) | 0.35 | ||||
| Operative time (per min) | 1.00 (0.99–1.00) | 0.74 | ||||
| Blood loss (per 100mL) | 1.09 (1.00–1.16) | <0.01* | 1.06 (0.99–1.14) | 0.07 | 1.08 (1.01–1.16) | 0.01* |
| Blood transfusion | 2.71 (1.75–4.19) | <0.01* | 1.43 (0.75–2.69) | 0.27 | 1.43 (0.75–2.73) | 0.39 |
| CDC grade ≥3 | 9.22 (5.78–14.71) | <0.01* | 11.9 (6.91–20.5) | <0.01* | ||
| CCI (per score) | 1.07 (1.05–1.08) | <0.01* | 1.07 (1.05–1.09) | <0.01* | ||
OR, odds ratio; CI, confidence interval; Alb, albumin; ASA, American Society of Anesthesiologists; BMI, body mass index; CRP, C-reactive protein; PSL, prednisolone; CDC, Clavien-Dindo classification; CCI, comprehensive complication index.
*p < 0.05 (significantly different).